Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Volker Heinemann

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1349-3321; OpenAlex author ID A5028938155, A5113984883. Sources: OpenAlex.

Their work

Papers
87 (first author 10, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
165
Papers, trials and grants by year

2011: 2 papers · 2012: 3 papers · 2013: 13 papers · 2014: 9 papers · 2015: 4 papers · 2016: 4 papers · 2017: 8 papers · 2018: 3 papers · 2019: none · 2020: 6 papers · 2021: 4 papers · 2022: 8 papers · 2023: 8 papers · 2024: 7 papers · 2025: 5 papers · 2026: 3 papers

Papers 50 of 87

  1. Circulating free bacterial DNA as a novel biomarker for monitoring therapy response in patients with advanced pancreatic cancer. Co-author DOI 10.1016/j.ejca.2026.117040↗
  2. Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP tri… Co-author DOI 10.1016/j.esmogo.2025.100274↗
  3. Distinct Mutation Signatures in Peripheral Blood Mitochondrial DNA from Liquid Biopsy Reveal Insights into Pancreatic Cancer. Co-author DOI 10.3390/cells15060527↗
  4. Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multic… Co-author DOI 10.1016/s2468-1253(25)00056-1↗
  5. PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer. Co-author DOI 10.1038/s41586-025-09017-8↗
  6. Tumor-Intrinsic Kinome Landscape of Pancreatic Cancer Reveals New Therapeutic Approaches. Co-author DOI 10.1158/2159-8290.cd-23-1480↗
  7. Sustained Clinical Response to Olaparib in a Patient with Metastatic Pancreatic Cancer and Somatic ATM Mutation R2034Ter: A Case Report. Co-author DOI 10.1159/000545975↗
  8. The Prognostic, Predictive and Clinicopathological Implications of KRT81/HNF1A- and GATA6-Based Transcriptional Subtyping in Pancreatic Cancer. Co-author DOI 10.3390/biom15030426↗
  9. Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116… First author DOI 10.1007/s00432-024-05827-x↗
  10. Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection? First author DOI 10.1007/s12094-023-03323-1↗
  11. Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial. Co-author DOI 10.1016/j.ejca.2024.113926↗
  12. Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades … Co-author DOI 10.1016/j.esmoop.2024.102944↗
  13. Corrigendum to "Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a… Co-author DOI 10.1016/j.esmoop.2024.103463↗
  14. Corrigendum to "Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a … Co-author DOI 10.1016/j.esmoop.2024.103705↗
  15. Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pan… Co-author DOI 10.1016/s2468-1253(24)00197-3↗
  16. Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison … Co-author DOI 10.1007/s00432-022-04112-z↗
  17. Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. Co-author DOI 10.1007/s11523-023-00950-0↗
  18. Regional hyperthermia with cisplatin added to gemcitabine versus gemcitabine in patients with resected pancreatic ductal adenocarcinoma: The HEAT randomised cl… Co-author DOI 10.1016/j.ejca.2022.12.009↗
  19. TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer. Co-author DOI 10.1038/s41416-023-02295-x↗
  20. Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrospective Cohort Study. Co-author DOI 10.1159/000528722↗
  21. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  22. Case of a Patient With Pancreatic Cancer With Sporadic Microsatellite Instability Associated With a BRAF Fusion Achieving Excellent Response to Immunotherapy. Co-author DOI 10.1200/po.22.00650↗
  23. Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for Assessing Adverse Events in Metastatic Pan… Co-author DOI 10.3390/curroncol30060436↗
  24. The impact of adjuvant therapy on outcome in UICC stage I pancreatic cancer. Co-author DOI 10.1002/ijc.34044↗
  25. [Treatment of metastatic pancreatic cancer]. Co-author DOI 10.1007/s00108-022-01334-8↗
  26. Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 stu… Co-author DOI 10.1016/j.esmoop.2022.100388↗
  27. Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, mu… Co-author DOI 10.1016/j.esmoop.2022.100552↗
  28. Novel systemic treatment approaches for metastatic pancreatic cancer. First author DOI 10.1080/13543784.2022.2037552↗
  29. Bacterial Lipopolysaccharide as a Negative Predictor of Adjuvant Gemcitabine Efficacy in Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkac039↗
  30. Comment on: "Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands: A Nationwide Analysis". First author DOI 10.1097/sla.0000000000005405↗
  31. Preanalytical Variables in the Analysis of Mitochondrial DNA in Whole Blood and Plasma from Pancreatic Cancer Patients. Co-author DOI 10.3390/diagnostics12081905↗
  32. Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel. Co-author DOI 10.1007/s12094-021-02620-x↗
  33. Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of… Last author DOI 10.1016/j.ejca.2020.12.029↗
  34. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEO… Co-author DOI 10.1016/s2468-1253(20)30330-7↗
  35. Quantitative Imaging Biomarkers of the Whole Liver Tumor Burden Improve Survival Prediction in Metastatic Pancreatic Cancer. Co-author DOI 10.3390/cancers13225732↗
  36. Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled… Co-author DOI 10.1007/s00432-019-03061-4↗
  37. Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 st… Co-author DOI 10.1038/s41416-020-01029-7↗
  38. [Erlotinib plus Gemcitabine in metastatic pancreatic cancer: Results from a non-interventional trial]. First author DOI 10.1055/a-1071-8177↗
  39. Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkz060↗
  40. Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional mul… Co-author DOI 10.1186/s12885-020-6636-7↗
  41. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcin… Co-author DOI 10.1200/jco.20.00590↗
  42. POLE gene hotspot mutations in advanced pancreatic cancer. Co-author DOI 10.1007/s00432-018-2746-x↗
  43. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospect… Co-author DOI 10.1016/j.ejca.2018.02.008↗
  44. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. First author DOI 10.1093/annonc/mdy417↗
  45. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study. Co-author DOI 10.1016/j.thromres.2017.06.021↗
  46. Improving post-surgical management of resected pancreatic cancer. First author DOI 10.1016/s0140-6736(17)31806-8↗
  47. Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. Last author DOI 10.1038/bjc.2017.115↗
  48. Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer. Co-author DOI 10.1080/2162402x.2017.1310358↗
  49. Mismatch-repair-deficient metastatic pancreatic ductal adenocarcinoma with a germline PALB2 mutation: unusual genetics, unusual clinical course. Last author DOI 10.1093/annonc/mdw564↗
  50. Oligometastatic Disease in Pancreatic Cancer - How to Proceed? Co-author DOI 10.1159/000455027↗

Closest collaborators

The 25 strongest of 165 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stefan Hubert Boeck · 74 shared papers, 2011–2026 · strength 7.48
  2. Michael Haas · 49 shared papers, 2012–2026 · strength 4.46
  3. Steffen Ormanns · 35 shared papers, 2013–2026 · strength 3.67
  4. Christoph Benedikt Westphalen · 25 shared papers, 2016–2025 · strength 2.88
  5. Stephan Krüger · 28 shared papers, 2014–2025 · strength 2.18
  6. Jens Werner · 15 shared papers, 2016–2023 · strength 1.86
  7. Volker Kunzmann · 12 shared papers, 2015–2026 · strength 1.73
  8. Klara Dorman · 10 shared papers, 2022–2026 · strength 1.72
  9. Jens Thomas Siveke · 14 shared papers, 2013–2026 · strength 1.57
  10. Michael Guenther · 9 shared papers, 2018–2026 · strength 1.57
  11. Dirk Waldschmidt · 12 shared papers, 2013–2024 · strength 1.42
  12. Thomas Jens Ettrich · 9 shared papers, 2018–2026 · strength 1.23
  13. Julia V. Mayerle · 9 shared papers, 2020–2025 · strength 1.22
  14. Danmei Zhang · 7 shared papers, 2023–2026 · strength 1.21
  15. Frank Kullmann · 9 shared papers, 2013–2026 · strength 1.16
  16. Stefan Holdenrieder · 12 shared papers, 2013–2026 · strength 1.01
  17. Brigitte Kimmel · 5 shared papers, 2022–2026 · strength 0.96
  18. Lena Weiss · 6 shared papers, 2023–2024 · strength 0.95
  19. Sai Agash Surendran · 4 shared papers, 2022–2026 · strength 0.88
  20. Anke Reinacher‐Schick · 7 shared papers, 2012–2024 · strength 0.82
  21. Ingo Hartlapp · 5 shared papers, 2021–2026 · strength 0.76
  22. Uwe M. Martens · 5 shared papers, 2021–2026 · strength 0.76
  23. Hana Algül · 5 shared papers, 2021–2026 · strength 0.76
  24. Kathrin Heinrich · 4 shared papers, 2023–2025 · strength 0.68
  25. Friedrich Anger · 4 shared papers, 2022–2026 · strength 0.67

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.